119th Congress · introduced in the House · Apr 28, 2026
POPCaP Authorization Act of 2026
Official title from Congress.gov
Latest action (Jun 12, 2026): Referred to the Subcommittee on Health.
View on Congress.govPolicy area: Armed Forces and National Security
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Subcommittee on Health.
Referred to the House Committee on Veterans' Affairs.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
1 citation.
PROSTATE CANCER FOUNDATION · lobbying firm or registrant: BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Veterans
$40,000
Paid to lobbying firm
Support for S.4993 (POPCaP Act of 2026 / Precision Oncology Program for Cancer of the Prostate Authorization Act of 2026) and House companion H.R. 8553. Support for Department of Veterans Affairs' Precision Oncology Centers.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing